About Elevation Pharmaceuticals
Elevation Pharmaceuticals is a biopharmaceutical company focused on developing new inhaled therapies for patients with respiratory disease. The Company was founded in 2008 by Cam Garner, formerly Chairman and CEO of Dura Pharmaceuticals, Bill Gerhart, formerly President and CEO of Mpex Pharmaceuticals, and Ahmet Tutuncu, formerly VP of Medical Affairs at Verus Pharmaceuticals. The Company's initial focus is on developing novel drug products for the underserved subpopulation of COPD patients not able to effectively control their disease with dry powder or metered dose inhalers. In August 2012, Elevation Pharmaceuticals was acquired by Sunovion Pharmaceuticals. The valuation of Elevation Pharmaceuticals was $430 million. Other terms of the deal were not released.
Missing: Elevation Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Elevation Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Elevation Pharmaceuticals News
Oct 1, 2020
October 01, 2020 10:08 AM Eastern Daylight Time SAN FRANCISCO & BOSTON--( BUSINESS WIRE )--Manifold, the applied AI company, announced a seed financing to support rapid growth, led by Jon Karlen, chairman of Acadian Software and former board member of PillPack. He was joined by Waterline Ventures where Robbie Greenglass led the investment and by former executives, investors, and board members of Amazon, Auris Health, Brightree, and Elevation Pharmaceuticals. Manifold partners with visionary leaders to make progress rapidly on AI mandates from C-suites and Boards through joint discovery and development programs. Manifold’s AI foundry brings together the infrastructure, algorithms, data, and multidisciplinary R&D team needed to rapidly forge market ready products. In contrast to other tools companies, Manifold’s AI scientists and software engineers work closely with biomedical scientists and engineers to invent novel solutions. Past collaborations have resulted in patents and publications in addition to products, for areas ranging from PK/PD modeling to HEOR and adherence. “Manifold is continuing to experience rapid growth, with revenues and team growing 100% this year and projected to double again next year. It’s a clear signal that our team and tools are uniquely suited to realizing the vast potential of data and AI to improve health outcomes,” said Vinay Seth Mohta, CEO and Co-Founder of Manifold. “At Manifold, we are on a mission to apply AI to the problems that matter.” “Several billion-dollar companies will be built in this space,” said investor Jon Karlen, chairman of Acadian Software and former board member of PillPack. “Manifold stands out among AI companies in achieving its current revenues and team size in such a capital efficient way. The company’s vision recognizes the distinct economic structure of an applied AI company relative to a traditional SaaS company.” “Machine learning is a valuable enabling technology in drug discovery and development and in clinical trial operations,” said Pravin Soni PhD, former CTO and Co-Founder of Elevation Pharmaceuticals and Patara Pharma. “Manifold’s growing partnerships in life sciences are a sign of the consensus that’s emerged on the potential over the last few years.” In the two years since the company began scaling its AI foundry, several global life sciences and healthcare companies have partnered with Manifold to discover and develop data and AI products. Manifold has also attracted technology, healthtech, and biotech veterans to its leadership and R&D teams from companies like Apple, AllScripts, Kyruus, Apixio, PatientPing, and TetraScience and from leading research universities. About Manifold Manifold is the applied AI company. Manifold’s AI foundry brings together the infrastructure, algorithms, data, and multidisciplinary R&D team needed to rapidly forge market ready products. Global companies partner with Manifold through joint discovery and development programs. For more information, visit www.manifold.ai . Contacts
Elevation Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Elevation Pharmaceuticals's headquarters?
Elevation Pharmaceuticals's headquarters is located at 11455 El Camino Real, San Diego.
What is Elevation Pharmaceuticals's latest funding round?
Elevation Pharmaceuticals's latest funding round is Acquired.
How much did Elevation Pharmaceuticals raise?
Elevation Pharmaceuticals raised a total of $60.24M.
Who are the investors of Elevation Pharmaceuticals?
Investors of Elevation Pharmaceuticals include Sunovion, Canaan Partners, Care Capital, Mesa Verde Venture Partners, TPG Biotech and 4 more.
Who are Elevation Pharmaceuticals's competitors?
Competitors of Elevation Pharmaceuticals include Radius, Aegerion Pharmaceuticals, Athenex, Selexys Pharmaceuticals, Neuraltus Pharmaceuticals, Diffusion Pharmaceuticals, Hyperion Therapeutics, Alvine Pharmaceuticals, KAI Pharmaceuticals, Quark Pharmaceuticals and 13 more.
Compare Elevation Pharmaceuticals to Competitors
Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Cobrek Pharmaceuticals is engaged in the research, development and commercialization of prescription drug therapies, delivery systems and applications that improve quality of life and enhance the lifestyle of patients across the adolescent and adult age-spectrum with particular attention to the needs of the aging population.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.
Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals is interested in building collaborative research programs with academic institutions. Ren Pharmaceuticals is developing data and useful reagents (e.g. antibodies, recombinant proteins) for studying the biology of renalase. We are interested in in-licensing and developing products that leverage our core strengths and complement our existing portfolio. Products with applications in kidney disease and associative diseases (e.g. cardio-renal diseases) are key areas of interest.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.